The anti-DLL4 antibody demcizumab in combination with paclitaxel showed some signs of clinical benefit (CBR 42% expressed as PR and SD) and acceptably manageable toxicity in patients with recurrent platinum-resistant ovarian cancer in a phase Ib trial. This evidence concerns the gene DLL4 and ovarian carcinoma.